These adverse events severely affect individuals infected with a pathogen after receiving a prior vaccine or infection-induced antibodies, resulting in enhanced infection via FcγR-expressing cells.822,823 There has been in vitro evidence of ADE for EBOV, MARV and beta-coronavirus.824–826 ADE was also observed for EBOV mAbs at subneutralizing concentrations, and this effect was not epitope restricted or independent of the neutralizing capacity or subclass of the mAbs.827 Fcγ receptor blockade reduced but did not abolish the ADE. The gene discussed is FCGR2A; the disease is infection.